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ABSTRACT
Introduction: Non-muscle invasive bladder cancer (NMIBC) is a highly recurrent disease with potential
progression to muscle invasive disease despite the standard bladder instillations with mitomycin C
(MMC) or Bacille Calmette–Guerin immunotherapy. Therefore, alternatives such as radiofrequency-
induced chemohyperthermia (RF-CHT) with MMC are being investigated. The mechanism explaining
the efficacy of RF-CHT is only partly understood. We examined whether RF-CHT results in higher MMC
tissue concentrations as compared to cold MMC instillation.
Patients and methods: Prior to a planned transurethral resection of bladder tumour (TURBT), patients
with stage Ta NMIBC were allocated to either (1) cold MMC instillation or (2) RF-CHT. After MMC instil-
lation, three biopsies were taken of both normal and tumour tissue. Biopsies were snap-frozen and
MMC tissue concentrations were analysed using ultra-performance liquid chromatography.
Results: Eleven patients were included of which six received RF-CHT. Ten patients had TaG2-LG/HG
papillary tumours at pathology. One patient in the RF-CHT group appeared to be free of malignancy
and was excluded from the analysis as no tumour biopsies were available. The median MMC concen-
tration in tumour tissue was higher in the RF-CHT group (median 665.00ng/g vs. 63.75ng/g, U¼ 51.0,
p¼ 0.018). Moreover, in both techniques the MMC concentration was lower in normal tissue compared
to tumour tissue. Tissue MMC concentration measurements varied substantially within, and between,
different patients from the same group.
Conclusion: Intravesical RF-CHT results in higher tumour MMC concentrations vs. cold MMC instillation
which contributes to its superior efficacy.
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Introduction
Bladder cancer is the 7th most commonly diagnosed cancer
in the male population worldwide, and the 11th most com-
monly diagnosed cancer when both genders are considered
[1–3]. It is predominantly seen in men living in developed
countries [2,3]. About 75% of patients present with non-
muscle invasive bladder cancer (NMIBC) at first diagnosis.
NMIBC is a highly recurrent disease with recurrence rates of
up to 52% after 5 years. Additionally, patients in the highest
risk group have a chance of progression to muscle invasive
disease reaching up to 20% [4]. The current EAU (European
Association of Urology) and AUA (American Urology
Association) guidelines advise a transurethral resection of the
bladder tumour (TURBT), followed by adjuvant intravesical
chemotherapy with typically mitomycin C (MMC), or immuno-
therapy with Bacille Calmette–Guerin (BCG) [5,6]. The exact
type and scheme of adjuvant instillations depend on the
patient’s risk category for recurrence and progression. This
risk for recurrence and progression necessitates a high fre-
quency of follow-up and treatments, leading to a significant
financial and logistic burden for the patient and the health-
care system [7,8]. Thus, improved treatment options for
NMIBC are needed.
A promising and effective alternative treatment appears to
be intravesical radiofrequency-induced chemohyperthermia
(RF-CHT), typically combining MMC with hyperthermia of the
bladder wall [9,10]. It compares favourably to standard MMC
instillations, with recurrence rates of 28% vs. 68% [9–11]. In a
meta-analysis based on four studies, the overall risk ratio of
RF-CHT was 0.41, indicating 59% less recurrences after RF-
CHT when compared to cold MMC alone [9]. Moreover, a
recent randomised clinical trial showed superiority of RF-CHT
over BCG immunotherapy as expressed by the 2-year recur-
rence free survival rates: 82% vs. 65%, respectively (p¼ 0.02,
Per Protocol analysis) [12].
However, the mechanism explaining the improved RF-CHT
efficacy compared to cold MMC is not completely clear [10].
One of the mainstay hypotheses is that hyperthermia enhances
tumour penetration of MMC by increasing tumour permeabil-
ity, while leaving the normal urothelium relatively unaffected.
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Studies with cold MMC instillations show six-fold higher
MMC concentrations in the urothelium and lamina propria
interface, and threefold higher MMC concentrations in the
lamina propria compared to the muscularis layer [13,14].
However, how tumour or normal tissue drug concentrations
relate after cold and warm intravesical application of MMC is
unknown.
The aim of our study was to evaluate whether a higher
uptake of MMC in tumour tissue after intravesical RF-CHT
might explain the superior efficacy as compared to cold
MMC instillations.
Patients and methods
Patients
Patients with primary or recurrent tumours suspect for papil-
lary NMIBC on office cystoscopy were included. Patients who
had previously received RF-CHT, or who had BCG or MMC
bladder instillations 6months prior to the cystoscopy were
excluded from participation. Additionally, patients were ineli-
gible in case of an allergy to MMC, a history of Carcinoma in
Situ, an indication for hexaminolevulinaat during TURBT, or
an American Society of Anesthesiologists score of >2.
Patients from our onco-urological centre were sequentially
included in the study from May 2012 to May 2016. The first
half of patients were treated with cold MMC, and subsequent
patients with RF-CHT.
Conduction of this study was approved by the Medical
Ethical Committee of Nijmegen/Arnhem for human experi-
ments. Informed consent was obtained before participation.
Experimental groups and procedures
Prior to a planned TURBT, patients were allocated to a cold
instillation group (MMC 40mg dissolved in 50mL of NaCl
0.9% which was left indwelling for 1–2 h, dependent on the
patient’s ability to retain the MMC-solution in the bladder),
or a warm instillation group using RF-CHT (two times MMC
20mg in 50mL of saline for 20–30min each, total dose of
40mg in up to 1 h). No randomisation or blinding was
performed.
Cold MMC was instilled using simple catheterisation at the
patient ward. RF-CHT was performed under full anaesthesia
at the operation theatre using the SynergoVR device [15]. In
short, a 20 Fr catheter with a 915MHz RF antenna, three
luminal thermocouples (TCs) and two urethral TCs was
placed. The bladder wall was heated to 42 ± 1 C and MMC
was circulated during two sessions of 20–30min. In between,
the bladder was emptied.
In both groups, the time between end of MMC instillation
and TURBT was kept below 15min. The bladder was rinsed
twice with 50mL of NaCl 0.9% to prevent measurement of
luminal MMC sticking to the mucosa. Immediately prior to
TURBT, three biopsies were taken of both normal and
tumour tissue. Location per biopsy was documented.
Biopsies were instantly snap-frozen using liquid nitrogen.
TURBT was performed under general anaesthesia according
to the standard protocol. Pathologic assessment was per-
formed for standard care.
MMC concentration assessment
Bladder biopsies were homogenised in control human
plasma (0.02 g/mL). Sample homogenates were stored at
80 C until analysis. After thawing, samples were mixed for
15 s and centrifuged (3min at 3000g). An aliquot of 50 mL
was deproteinised with 150 mL of acetonitrile–methanol (1:1,
v/v). Samples were shaken (10min at 1250 rpm) and centri-
fuged (15min at 23 100g). The clear supernatants were
dried under a gentle stream of nitrogen (40 C) and sam-
ples were reconstituted in 50 mL of 10mM ammonium acet-
ate in water. A volume of 2–10 mL was injected onto an
Acquity BEH column (50 2.1mm ID, 1.7 mm particle size)
using an I Class Acquity UPLC (Ultra Performance Liquid
Chromatography) system (Waters, Milford, MA). Eluent A
consisted of 5mM ammonium formate–formic acid (99.9:0.1,
v/v) and Eluent B of methanol, and the flow was set to
250 mL/min. Gradient elution was applied and initially
(0–1.50min) 10% B was pumped through the column. From
1.51 to 2.50min the eluent consisted of 90% B and from
2.60 to 5.00min the column was equilibrated to the initial
conditions. The outlet of the column was connected to a
triple quadrupole mass spectrometer (API5500 trap, Sciex,
Framingham, MA). For MMC, a transition of m/z 335–242
was optimised and the retention time of the analyte was
2.3min.
For the quantification, control human bladder homoge-
nates (0.0200 g/mL in control human plasma) were processed
until dried extracts were obtained. These samples were
reconstituted in aqueous MMC working solutions to obtain
calibration standards in the range from 0.5 to 50 ng/mL.
MMC area vs. concentration plots were fitted using linear
regression with a weighting factor of 1/x2. Average drug con-
centrations per tissue sample were calculated by dividing the
total amount of drug recovered by the total weight of the
tissue.
Statistics
For demographics, medians were assessed for continuous
variables. Based on the median values per patient and tissue
type, the Mann–Whitney U test was used for comparison of
unpaired observations (i.e. warm vs. cold MMC), and the
Wilcoxon Signed Rank test for paired observations (i.e. nor-
mal vs. tumour tissue). All analyses were performed using
SPSS software, version 22 (IBM Corp., Armonk, NY, USA), with
a two-sided p< 0.05 considered statistically significant.
Results
In total, 11 patients participated in this study. Five were allo-
cated to cold MMC instillations, six patients received MMC-
based RF-CHT. The additional 6th patient for the RF-CHT
group was included since one patient had benign pathology
after TURBT and the associated biopsies were not evaluated
INTERNATIONAL JOURNAL OF HYPERTHERMIA 989
for MMC concentration. This patient was excluded from ana-
lysis. All other patients (n¼ 10) had pTaG2, either low grade
(LG) or high grade (HG), bladder cancer. Patient characteris-
tics are shown in Table 1.
Normal vs. tumour MMC concentration
The MMC concentration in tumour tissue was higher than
in normal mucosa tissue within the RF-CHT group (sum of
ranks 15 vs. 0, z¼2.023, p¼ 0.043, Figure 1). This differ-
ence remained after all tumour tissue MMC values were
piled together and compared to all normal tissue values
regardless of treatment group (sum of ranks 53 vs. 2,
z¼2.599, p¼ 0.009). No significant difference was found
between tumour and normal tissue in tissue derived from
the cold MMC group (sum of ranks 13 vs. 2, z¼1.483,
p¼ 0.138).
Cold vs. RF-CHT MMC instillation
Median MMC concentration in tumour tissue was significantly
higher in the RF-CHT group as compared to the cold MMC
group (median 665.00 ng/g vs. 63.75 ng/g, U¼ 51.0, p¼ 0.018,
Figure 1). Normal tissue MMC concentration did not differ
between both groups (median 67.00 ng/g vs. 24.50 ng/g,
U¼ 100.5, p¼ 0.619, Figure 1).
Inter- and intrapatient variability in tissue drug uptake
Interestingly, tissue concentration measurements varied sub-
stantially within both treatment groups and tissue types,
even within patients (Table 2). The lowest measured tissue
concentration was 9.3 ng/g (normal tissue after cold MMC),
the highest tissue concentration was 3320 ng/g (tumour tis-
sue after RF-CHT). These differences were not associated with
the biopsy location. Indeed, MMC tissue concentration dif-
fered strongly: (1) within the same biopsy location, (2) within
the same tissue type (i.e. within tumour tissue) and (3)
between different patients (a high interpatient variation),
especially for the tumour concentrations.
Discussion
Treatment of patients with NMIBC with intravesical RF-CHT
has been shown to be more effective than treatment with
intravesical chemotherapy alone [10]. Thus far, the mechan-
ism explaining this enhanced efficacy has remained elusive.
Here, we show that RF-CHT leads to significantly higher drug
accumulation in NMIBC compared to cold chemotherapy
installation, likely explaining part of its superior effect.
Interestingly, drug concentrations in normal urothelium were
not affected by RF-CHT, whilst tumour drug concentrations
were higher in both groups, suggesting higher drug penetra-
tion in tumours, unrelated to heating. Tissue drug uptake dif-
fered substantially within – and between – individual
patients, regardless of tissue type or biopsy location.
The bladder urothelium is a highly impermeable barrier to
luminal molecules, also when compared to pelvic or ureteral
urothelium, thus protecting underlying tissue from excreted
fluid and molecules [14]. Our results suggest that RF-CHT
Figure 1. Boxplot showing the concentrations of MMC in both groups for nor-
mal and tumour tissue. Median values are depicted by the bold horizontal bars.
: Outlier (i.e. >1.5 interquartile range from 3rd quartile). D: Extreme outlier
(i.e. >3 interquartile range from 3rd quartile). MMC, mitomycin C; RF,
radiofrequency.
Table 1. Patient characteristics per treatment group.
Characteristic Cold MMC group RF-CHT (warm) MMC group
Patients, n 5 5
Male 5 2
Female 0 3
Median age at TURBT, y (range) 68 (48–73) 69 (42–79)
Previous NMIBC, n
Primary disease 3 4
Recurrent LG disease 2 1
Pathology result, n
pTaG2-LG 5 3
pTaG2-HG 0 2
Median intravesical MMC dwell time, min (range, n)a 94 (65–121, n¼ 4) 50 (45–50, n¼ 4)
Median time between MMC out and normal biopsy, min (range, n)a 12.5 (8–18, n¼ 4) 15 (10–20, n¼ 3)
Median time between MMC out and tumour biopsy, min (range, n)a 8 (5–10, n¼ 4) 10 (8–15, n¼ 3)
Median average temperature during treatment, C (range, n) N/A 41,6 (41.0–41.8, n¼ 5)
an< 5 due to incomplete documentation of this characteristic.
HG: high grade; LG: low grade; MMC: mitomycin C; NMIBC: non-muscle invasive bladder cancer; N/A: not applicable; RF-CHT: radiofrequency
induced chemohyperthermia; TURBT: transurethral resection of bladder tumour.
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exerts negligible effects on the normal urothelium barrier
function since MMC concentrations are low and similar to
concentrations after cold MMC administration. In contrast,
drug accumulation in tumours was increased, regardless of
the mode of administration. This is most likely the conse-
quence of impaired cell–cell contact, leading to enhanced
MMC accumulation. It has been well established that malig-
nant cells lose their original functional properties such as the
urothelial barrier function, and cell–cell contact may be
impaired as they dedifferentiate [14,16–19].
Application of hyperthermia enhanced MMC accumulation,
most likely because it impairs the barrier functions even fur-
ther. This higher accumulation of MMC in tumour tissue
almost certainly explains the improved efficacy of RF-CHT
[19]. In addition, drug potentiation by hyperthermia has been
suggested, although to the best of our knowledge this has
not yet been confirmed. Nevertheless, direct hyperthermic
damage to DNA, RNA and proteins, leading to protein syn-
thesis inhibition, failing repair mechanisms due to altered
intracellular metabolism, cell death and apoptosis can also
contribute to the RF-CHT efficacy [10]. Moreover, hyperther-
mia might boost the immune system possibly resulting in an
increased cellular immune response and autovaccination
against tumour cells [20]. Lastly, tumour vasculature is less
responsive and thus less efficient in dissipating heat, result-
ing in a higher local temperature than in non-cancerous cells.
This possibly contributes to a higher treatment specificity for
tumour tissue, also at the cellular level [10]. Intriguingly, RF
might also induce a temperature-independent effect on cell
drug permeability and metabolism [21–23].
These proposed modes of action explain why RF-CHT is
superior compared to cold MMC instillations [10] and even
BCG immunotherapy [12] – the gold standard therapy in
intermediate to high risk NMIBC patients [5]. We now dem-
onstrate increased drug accumulation in tumour as one of
the main mechanisms of RF-CHT in NMIBC.
The tissue MMC concentrations found in our study are
substantially lower than values published by others
[13,14,24], which probably is methodology derived. In two
pharmacokinetic studies, MMC concentrations in normal
human bladder tissue after cold MMC instillation pre-cystec-
tomy were on average 15–40 times higher [13,24]. However,
these MMC concentrations were derived from a small subset
of patients (7/24) selected based on the highest urine con-
centrations or swiftly ligated vasculature probably biasing the
MMC concentrations toward higher levels. Indeed, the other
patients (17/24) had substantially lower bladder wall MMC
concentrations of <1lg/g, and even <0.1 lg/g in the major-
ity of cases (n¼ 13), approaching our values for normal blad-
der tissue after cold MMC [13]. Remarkably, in their study the
average MMC concentration in tumour-bearing tissues was
only about 40% higher than in adjacent normal tissues
(n¼ 6, p¼ 0.01) [24], whereas we found a 160% higher MMC
concentration in tumour compared to normal tissue. No tis-
sue after warm MMC was evaluated in these studies.
The different methodology of these studies plays a role in
our different findings. In our study, a biopsy reaching about
1mm deep was obtained and homogenised without dissec-
tion into different layers. Thus, the MMC amount was aver-
aged over both the mucosa and submucosa layers. In
contrast, Wientjes et al. dissected samples into a mucosa,
submucosa and muscularis layer before defining the concen-
trations, potentially explaining the lower MMC concentrations
measured in our samples. In addition, these studies instilled
1.2–5 times higher dosages of MMC. We evaluated patients
undergoing TURBT after flushing the bladder with saline to
eradicate luminal MMC from the sample. The above-men-
tioned studies sampled the full thickness bladder wall with-
out prior flushing. This possibly explains the higher
concentrations found by others.
The high inter- and intra-individual variability of MMC
accumulation observed in our study is most likely a reflection
of a combination of tumour heterogeneity, and different
locations, sizes and anatomical depths of our biopsies (i.e.
methodology) which influenced MMC exposure as well as the
calculated amount of MMC per gram of tissue. Tumour het-
erogeneity (different tissue and membrane barrier function),
and anatomical variations in both tumour and bladder wall
orientation (i.e. mucosal folds) will result in variable MMC
Table 2. MMC concentrations per patient, treatment group, tissue type and
location.
Cold MMC group RF-CHT (warmed) MMC group
Patient
(tumour n)
MMC amount in
biopsy (ng MMC/g
tissue)
Patienta
(tumour n)
MMC amount in
biopsy (ng MMC/g
tissue)
1 (1) 6 (4)
Normal 9.3 – PW Normal 58.4 – PW
22.9 – left SW 177.0 – PW
12.8 – right SW 12.8 – PW
Tumour 23.6 – left SW Tumour 1365.0 – left SW
35.8 – left SW 306.8 – right SW
40.9 – left SW 887.5 – right SW
2 (3) 8 (1)
Normal 30.4 – right SW Normal 20.8 – PW/dome
220.0 – right SW 18.3 – PW/dome
9.4 – left SW 18.8 – PW/dome
Tumour 3070.0 – right PW Tumour 288.0 – right SW
1300.0 – right PW 139.5 – right SW
540.0 – right PW 1000.0 – right SW
3 (1) 9 (1)
Normal 24.0 – PW Normal 152.5 – PW/SW
9.3 – trigonum 25.1 – PW/SW
24.5 – left SW 214.5 – PW/SW
Tumour 272.0 – left SW Tumour 665.0 – right SW
29.1 – left SW 3320.0 – right SW
–b – 520.0 – right SW
4 (1) 10 (1)
Normal 392.0 – PW Normal 12.0 – left SW
254.0 – PW Left 104.0 – left SW
223.5 – PW 134.5 – trigonum
Tumour 745.0 – left SW Tumour 910.0 – right SW
752.5 – left SW 2960.0 – right SW
60.5 – left SW 135.0 – right SW
5 (4) 11 (1)
Normal 271.0 – PW Normal 67.0 – PW
82.0 – left SW 955.0 – right SW
11.8 – trigonum 90.0 – PW
Tumour 14.5 – right SW Tumour 1355.0 – left SW
67.0 – right SW 580.0 – left SW
10.0 – right SW 62.0 – left SW
aPatient 7 had a benign pathology result after TURBT and was therefore not
evaluated.
bNo third tumour biopsy was available for patient 3.
MMC: mitomycin C; PW: posterior wall; RF-CHT: radiofrequency induced che-
mohyperthermia; SW: side wall; TURBT: transurethral resection of bladder
tumour.
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exposure. Temperature differences over the bladder wall
might also play a role but do not fully explain the observed
variability since this variability was also present after cold
MMC instillation, and was also observed in a study in dogs
without bladder cancer [25].
The median intravesical MMC dwell time was substan-
tially longer for cold MMC instillation (94min) compared to
RF-CHT (50min). This likely resulted in a higher total expos-
ure to MMC in the cold MMC group. Assuming an average
urine production of 50mL/30min, this implies that after
90min and a starting dose of 40mg MMC in 50mL, the
intravesical MMC concentration still is 0.2mg/mL, being
higher than the threshold of 0.12mg/mL for effective MMC
exposure [13]. In comparison, the MMC concentration after
30min of RF-CHT using the lower dose of 20mg MMC – as
was done in our study – is 0.13mg/mL [26]. Using hyper-
thermia, the MMC concentration is known to decrease
much faster compared to cold MMC instillation due to add-
itional dilution, absorption and degradation of the drug
[26]. Thus, the longer intravesical dwell time for cold MMC
merely underlines the observed advantage of RF-CHT over
cold MMC in reaching higher MMC accumulation in tumour
tissue. Additionally, optimalisation of the intravesical drug
instillation by increasing dwell time, reducing drug dilution,
inducing urine alkalinisation, and increasing dose to 2mg
MMC/mL is known to enhance efficacy [27].
A drawback of the current study is the limited number of
patients studied. Nevertheless, our results strongly suggest
that RF-CHT drives higher drug accumulation which substan-
tially contributes to the superiority of intravesical RF-CHT
over cold MMC.
Conclusion
Warm application of MMC using intravesical RF-induced
hyperthermia results in a higher drug accumulation in papil-
lary NMIBC lesions as compared to a standard cold MMC
bladder instillation, partially explaining its improved efficacy.
It is credible that multiple factors contribute to the ultimate
MMC concentration in tumour tissue explaining the clinical
heterogeneity in intravesical treatment response in different
patients. Drug concentrations typically were high in tumour
tissue, and low in normal tissue, although a high inter- and
intrapatient variability in MMC concentration was observed,
supporting a multifactorial mechanism for tissue MMC
accumulation.
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